Gentamicin pharmacokinetics during continuous venovenous hemofiltration in critically ill septic patients

被引:11
作者
Petejova, Nadezda [1 ,2 ]
Zahalkova, Jana [3 ,4 ,5 ]
Duricova, Jana
Kacirova, Ivana
Brozmanova, Hana
Urbanek, Karel [6 ]
Grundmann, Milan
Martinek, Arnost [2 ]
机构
[1] Univ Hosp Ostrava, Dept Internal Med, Ostrava 70852, Czech Republic
[2] Univ Ostrava, Fac Med, Dept Internal Med, Ostrava, Czech Republic
[3] Univ Hosp Olomouc, Dept Internal Med, Olomouc, Czech Republic
[4] Univ Hosp Olomouc, Fac Med, Olomouc, Czech Republic
[5] Hosp Sternberk, Stredomoravska Nemocnicni, Olomouc, Czech Republic
[6] Palacky Univ Olomouc, Univ Hosp, Olomouc, Czech Republic
关键词
Critically ill patients; Sepsis; Acute kidney injury; Continuous renal replacement therapy; Gentamicin dosing; Therapeutic drug monitoring; ANTIBIOTICS; ELIMINATION; NETILMICIN; ADSORPTION; THERAPY; VOLUME;
D O I
10.1179/1120009X12Z.0000000006
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective: Current dosing recommendations for administration of gentamicin to septic patients with acute kidney injury (AKI) on continuous venovenous hemofiltration (CVVH) at a filtration rate of 45 ml/kg/h are missing. Aim: To describe gentamicin pharmacokinetics and to find an optimal dosing regimen in patients on CVVH. Methods: Seven adult patients were included. Patients received loading dose of 240 mg followed by application of maintenance dose every 24 hours. Maintenance dose was adjusted according to gentamicin C-max/MIC ratio and drug levels simulation using a pharmacokinetic programme. Results: Median total clearance (0.59-0.79 ml/min/kg) was similar to patients with normal renal function; median volume of distribution was higher than observed in non-septic patients (about 0.5 l/kg versus 0.25 l/kg). Patients with diuresis required an increase of gentamicin dose to reach C-max/MIC ratio. Conclusion: Septic patients with AKI on CVVH (45 ml/kg/h) require a loading dose of 240 mg, followed by therapeutic drug monitoring to optimize maintenance dose.
引用
收藏
页码:107 / 112
页数:6
相关论文
共 50 条
[21]   Cytokine removal in septic patients with continuous venovenous hemofiltration [J].
Heering, P ;
Grabensee, B ;
Brause, M .
KIDNEY & BLOOD PRESSURE RESEARCH, 2003, 26 (02) :128-134
[22]   Population Pharmacokinetics of Cefuroxime in Critically Ill Patients Receiving Continuous Venovenous Hemofiltration With Regional Citrate Anticoagulation and a Phosphate-Containing Replacement Fluid [J].
Janssen, Paddy K. C. ;
Foudraine, Norbert A. ;
Burgers, Desiree M. T. ;
Neef, Kees ;
le Noble, Jos L. M. L. .
THERAPEUTIC DRUG MONITORING, 2016, 38 (06) :699-705
[23]   The impact of continuous renal replacement therapy on antibiotic pharmacokinetics in critically ill patients [J].
Fiore, Marco ;
Peluso, Lorenzo ;
Taccone, Fabio Silvio ;
Hites, Maya .
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2021, 17 (05) :543-554
[24]   Pharmacokinetics of Ertapenem in Critically Ill Patients Receiving Continuous Venovenous Hemodialysis or Hemodiafiltration [J].
Eyler, Rachel F. ;
Vilay, A. Mary ;
Nader, Ahmed M. ;
Heung, Michael ;
Pleva, Melissa ;
Sowinski, Kevin M. ;
DePestel, Daryl D. ;
Soergel, Fritz ;
Kinzig, Martina ;
Mueller, Bruce A. .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2014, 58 (03) :1320-1326
[25]   Circuit Survival during Continuous Venovenous Hemodialysis versus Continuous Venovenous Hemofiltration [J].
Califano, Alfonso Maria ;
Bitker, Laurent ;
Baldwin, Ian ;
Fealy, Nigel ;
Bellomo, Rinaldo .
BLOOD PURIFICATION, 2020, 49 (03) :281-288
[26]   Regional citrate anticoagulation in continuous venovenous hemofiltration in critically ill patients with a high risk of bleeding [J].
Palsson, R ;
Niles, JL .
KIDNEY INTERNATIONAL, 1999, 55 (05) :1991-1997
[27]   Pharmacokinetics of Micafungin in Critically Ill Patients Receiving Continuous Venovenous Hemodialysis With High Cutoff Membranes [J].
Tenorio-Canamas, Teresa ;
Grau, Santiago ;
Luque, Sonia ;
Fortun, Jesus ;
Liano, Fernando ;
Roberts, Jason A. .
THERAPEUTIC DRUG MONITORING, 2019, 41 (03) :376-382
[28]   Doripenem population pharmacokinetics and dosing requirements for critically ill patients receiving continuous venovenous haemodiafiltration [J].
Roberts, Jason A. ;
Udy, Andrew A. ;
Bulitta, Juergen B. ;
Stuart, Janine ;
Jarrett, Paul ;
Starr, Therese ;
Lassig-Smith, Melissa ;
Roberts, Natasha A. ;
Dunlop, Rachel ;
Hayashi, Yoshiro ;
Wallis, Steven C. ;
Lipman, Jeffrey .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2014, 69 (09) :2508-2516
[29]   Pharmacokinetics of flucytosine in a critically ill patient on continuous venovenous hemodiafiltration [J].
Greene, Rebecca A. ;
Adams, Kathleen K. ;
Rogers, Ralph D. ;
Berard-Collins, Christine ;
Lorenzo, Michael P. .
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2020, 77 (08) :609-613
[30]   Effects of continuous venovenous hemofiltration on vancomycin trough concentrations in critically ill children [J].
Peng, Lengyue ;
Gao, Yawen ;
Zhang, Guangli ;
Tian, Xiaoyin ;
Xu, Huiting ;
Yu, Qinghong ;
Cheng, Jie ;
Li, Yuanyuan ;
Li, Qinyuan ;
Chen, Yingfu ;
Zhao, Wei ;
Luo, Zhengxiu .
ANNALS OF TRANSLATIONAL MEDICINE, 2021, 9 (03)